Compare TIMB & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TIMB | ALKS |
|---|---|---|
| Founded | 1998 | 1987 |
| Country | Brazil | Ireland |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9B | 8.7B |
| IPO Year | 2020 | 2012 |
| Metric | TIMB | ALKS |
|---|---|---|
| Price | $17.81 | $48.48 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 14 |
| Target Price | $25.10 | ★ $43.43 |
| AVG Volume (30 Days) | 565.4K | ★ 1.6M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | ★ 4.88% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,475,899,000.00 |
| Revenue This Year | $8.47 | $24.26 |
| Revenue Next Year | $4.80 | $4.47 |
| P/E Ratio | $15.81 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.14 | $25.17 |
| 52 Week High | $28.22 | $55.67 |
| Indicator | TIMB | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 35.82 | 44.95 |
| Support Level | $17.14 | $47.66 |
| Resistance Level | $22.74 | $51.25 |
| Average True Range (ATR) | 0.41 | 1.55 |
| MACD | 0.04 | -0.16 |
| Stochastic Oscillator | 41.52 | 29.21 |
TIM, which is 67%-owned by Telecom Italia, is the third-largest wireless carrier in Brazil, with 62 million subscribers, equal to about 23% of the market. The firm owns 49% of I-Systems, an infrastructure partnership that is expanding its network footprint across Brazil. I-Systems can provide broadband service to about 8 million locations, including 6.5 million with fiber, equal to 10%-15% of the country. TIM leases capacity on the venture's network to serve retail broadband customers under the UltraFibra brand, but it has agreed to buy out its joint venture partner in 2026 and will take full ownership of these assets. TIM also resells fiber network access from other providers.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.